Perspective

Biology

Could We Switch Off Autoimmunity?

Eugene Gibson*
University of Nevada, Reno, 1664 N Virginia St, Reno, NV 89557, USA
*: All correspondence should be sent to: Dr. Eugene Gibson
Author's Contact: Dr. Eugene Gibson, Ph.D., E-mail: eugene.gibson@hotmail.com
DOI: https://doi.org/10.15354/si.24.pe183
Funding: No funding source declared.
COI: The author declares no competing interest.
AI Declaration: The author affirms that artificial intelligence did not contribute to the process of preparing the work.

Autoimmunity transpires when the immune system erroneously targets healthy cells, leading to a range of autoimmune disorders. Although medications are available to alleviate symptoms and decelerate disease progression, a definitive cure for autoimmunity continues to be unattainable. Research in immunology and medical science is perpetually advancing, with novel potential findings arising. A viable strategy for tackling autoimmunity involves employing medicines that target the fundamental mechanisms responsible for immune system dysfunction. Certain drugs may regulate certain immune responses or obstruct inflammatory pathways associated with autoimmune illnesses. Moreover, gene-editing technologies such as CRISPR-Cas9 present possible avenues for altering genes associated with autoimmunity and maybe "disabling" the autoimmune response entirely. Despite existing hurdles, including the assurance of therapeutic efficacy and safety, these novel techniques have the potential to transform the management of autoimmunity in the future.

Keywords: Autoimmunity; Genetic Switch; CRISPR-Cas9; Dysfunction; Strategic Pathways

Science Insights, 2024 December 31; Vol. 45, No. 6, pp.1677-1680.

AUTOIMMUNITY is a pervasive and intricate phenomenon in which the immune system mistakenly targets its own cells, tissues, and organs (Smith & Germolec, 1999). This can result in a diverse array of autoimmune diseases, such as rheumatoid arthritis, lupus, multiple sclerosis, type 1 diabetes, and many others (Jaycox et al., 2024; Pisetsky, 2023; Wang et al., 2015). These conditions are frequently chronic and debilitating, and there is currently no known cure (Műzes & Sípos, 2023; Rosenblum et al., 2012). Nevertheless, the issue of whether it is possible to deactivate autoimmunity has been posed by recent developments in biotechnology and immunology (Carballido & Santamaría, 2019).

One promising method of managing autoimmunity is to manipulate the immune system to reestablish balance and tolerance (Bluestone & Bour, 2012; Smilek & Clair, 2015). This could potentially be accomplished by employing immunemodulatory medications, which have the ability to either activate or suppress specific immune responses in order to target autoimmune processes (Forero et al., 2007; Rosenblum et al., 2012). Drugs such as corticosteroids and immunosuppressants

are frequently employed to mitigate excessive immune responses in conditions such as lupus and rheumatoid arthritis (Balogh et al., 2024; Bijlsma et al., 2008; Busillo & Cidlowski, 2013; Fauci et al., 2016).

Stem cell therapy is another potential approach to inhibiting autoimmunity (Dazzi et al., 2007; Sampath et al., 2021). It may be feasible to reverse autoimmune processes and facilitate healing by employing stem cells to regenerate damaged tissues and restore normal immune function. Although still in the experimental phase, stem cell therapy has demonstrated significant potential in the treatment of a diverse array of autoimmune diseases, such as multiple sclerosis and type 1 diabetes (Fox et al., 2014; Wang et al., 2018; Yordanova & Ivanova-Todorova, 2023).

There is an increasing interest in the use of biologics to target specific molecules and pathways implicated in autoimmunity, in addition to drug therapies and stem cell-based approaches (Kwiatkowski et al., 2020; Mihaylova & Tchorbanov, 2011; Moroncini et al., 2017; Papanastasiou et al., 2008; Willyard, 2024). Biologics are genetically engineered proteins that can regulate immune responses and inhibit inflammatory signals, thereby offering a more effective and precise treatment for autoimmune diseases (Oh & Payne, 2022; Rosenblum et al., 2012; Talal, 1989). These medications have transformed the treatment of autoimmune disorders, such as psoriasis and rheumatoid arthritis, by providing patients with new hope (Feldmann & Steinman, 2005; Ogata & Tanaka, 2012).

New opportunities for immune system modification to prevent or treat autoimmunity have emerged as a result of advancements in gene editing technologies, including CRISPR-Cas9 (Abdelnour et al., 2021; Li et al., 2023; Munshi, 2016; Newman & Ausubel, 2016). It may be feasible to rectify the underlying genetic defects and reestablish the normal immune function by targeting and altering specific genes that are involved in autoimmune processes (Cai et al., 2016; Lee et al., 2022). While gene editing is still in the early phases of development, it has the potential to address autoimmunity at its source.

The complexity of the immune system and the diversity of autoimmune diseases continue to present a formidable challenge in the process of turning off autoimmunity, despite these thrilling advancements (Bluestone & Tang, 2018; Carballido & Santamar á, 2019; George & Shoenfeld, 2000; Theofilopoulos et al., 2017; Zhai et al., 2021). Additionally, the current treatment strategies are associated with risks and limitations, such as immune suppression, high costs, and adverse effects (Bilbao et al., 2014; Romano et al., 2019). As a result, there is a necessity for ongoing research and innovation to create safer, more effective, and personalized strategies for managing autoimmunity (Chandrashekara, 2012; Mosanya & Isaacs, 2018).

The utilization of immunotherapy to re-educate the immune system and foster self-tolerance is a prospective research avenue (Alderuccio et al., 2011; Papanastasiou et al., 2008; Talal, 1989; Thatte et al., 2024). It may be feasible to instruct immune cells to identify and disregard self-antigens by subjecting them to specific antigens or molecules that are linked to autoimmunity, thereby averting autoimmune reactions (Bansal ‐ Pakala & Croft, 2001; Li et al., 2006; Pearson et al., 2017; Perico et al., 2024; Steinman, 2004; Willyard, 2024). This method has the potential to achieve long-lasting remission in patients with autoimmune diseases and to reverse autoimmunity.

The gut microbiome's function in modulating immune responses and preserving immune tolerance is another critical component of managing autoimmunity (Fishman & Thomson, 2015; Mousa et al., 2022; Willyard, 2024). According to recent research, the development of autoimmune diseases is linked to dysbiosis, or an imbalance in gut flora (Bakinowska et al., 2024; Campbell, 2014; Li et al., 2018; Sun et al., 2024; Xu et al., 2019). It may be feasible to restore the immune system and prevent autoimmune reactions by focusing on the gut microbiome through dietary interventions, probiotics, or fecal transplants.

Therefore, although turning off autoimmunity may appear to be an overwhelming endeavor, recent developments in immunology, biotechnology, and personalized medicine provide patients with autoimmune diseases with new optimism. Individuals with autoimmune disorders may be able to achieve enduring remission, reverse autoimmune processes, and restore immune tolerance by utilizing the body's own immune system and novel therapies. One day, we may be able to turn off autoimmunity and offer a cure for these debilitating conditions through ongoing research and innovation.■

References

Abdelnour, S. A., Xie, L., Hassanin, A. A., Zuo, E., & Lu, Y. (2021). The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Inherited Diseases. Frontiers in Cell and Developmental Biology, 9. DOI: https://doi.org/10.3389/fcell.2021.699597

Alderuccio, F., Nasa, Z., Chung, J., Ko, H., Chan, J., & Toh, B. (2011). Hematopoietic Stem Cell Gene Therapy as a Treatment for Autoimmune Diseases. Molecular Pharmaceutics, 8(5), 1488–1494. DOI: https://doi.org/10.1021/mp2001523

Bakinowska, E., Stańska, W., Kiełbowski, K., Szwedkowicz, A., Boboryko, D., & Pawlik, A. (2024). Gut Dysbiosis and Dietary Interventions in Rheumatoid Arthritis—A Narrative Review. Nutrients, 16(18), 3215. DOI: https://doi.org/10.3390/nu16183215

Balogh, L., Oláh, K., Sánta, S., Majerhoffer, N., & Németh, T. (2024). Novel and potential future therapeutic options in systemic autoimmune diseases. Frontiers in Immunology, 15. DOI:

https://doi.org/10.3389/fimmu.2024.1249500
Bansal-Pakala, P., & Croft, M. (2001). Breaking Immunological Tolerance through OX40 (CD134). The Scientific World JOURNAL, 1, 633–635. DOI: https://doi.org/10.1100/tsw.2001.341
Bijlsma, J. W., Buttgereit, F., Cutolo, M., & Da Silva, J. a. P. (2008). Chapter 20 Hormonal Modulation of Autoimmune Diseases: Glucocorticoids. In Technical report (pp. 229–240). DOI: https://doi.org/10.1016/s1571-5078(07)00220-6
Bilbao, D., Luciani, L., Johannesson, B., Piszczek, A., & Rosenthal, N. (2014). Insulin‐like growth factor‐1 stimulates regulatory T cells and suppresses autoimmune disease. EMBO Molecular Medicine, 6(11), 1423–1435. DOI: https://doi.org/10.15252/emmm.201303376
Bluestone, J. A., & Bour-Jordan, H. (2012). Current and Future Immunomodulation Strategies to Restore Tolerance in Autoimmune Diseases. Cold Spring Harbor Perspectives in Biology, 4(11), a007542. DOI: https://doi.org/10.1101/cshperspect.a007542
Bluestone, J. A., & Tang, Q. (2018). T reg cells—the next frontier of cell therapy. Science, 362(6411), 154–155. DOI: https://doi.org/10.1126/science.aau2688
Busillo, J. M., & Cidlowski, J. A. (2013). The five Rs of glucocorticoid action during inflammation: ready, reinforce, repress, resolve, and restore. Trends in Endocrinology and Metabolism, 24(3), 109–119. DOI: https://doi.org/10.1016/j.tem.2012.11.005
Cai, L., Fisher, A. L., Huang, H., & Xie, Z. (2016). CRISPR-mediated genome editing and human diseases. Genes & Diseases, 3(4), 244–251. DOI: https://doi.org/10.1016/j.gendis.2016.07.003
Campbell, A. W. (2014). Autoimmunity and the Gut. Autoimmune Diseases, 2014, 1–12. DOI: https://doi.org/10.1155/2014/152428
Carballido, J. M., & Santamaria, P. (2019). Taming autoimmunity: Translating antigen-specific approaches to induce immune tolerance. The Journal of Experimental Medicine, 216(2), 247–250. DOI: https://doi.org/10.1084/jem.20182287
Chandrashekara, S. (2012). The treatment strategies of autoimmune disease may need a different approach from conventional protocol: A review. Indian Journal of Pharmacology, 44(6), 665. DOI: https://doi.org/10.4103/0253-7613.103235
Dazzi, F., Van Laar, J. M., Cope, A., & Tyndall, A. (2007). Cell therapy for autoimmune diseases. Arthritis Research & Therapy, 9(2), 206. DOI: https://doi.org/10.1186/ar2128
Fauci, A. S. (1983). Corticosteroids in Autoimmune Disease. Hospital Practice, 18(10), 99–114. DOI: https://doi.org/10.1080/21548331.1983.11702661
Feldmann, M., & Steinman, L. (2005). Design of effective immunotherapy for human autoimmunity. Nature, 435(7042), 612–619. DOI: https://doi.org/10.1038/nature03727
Fishman, J., & Thomson, A. (2015). Clinical Implications of Basic Science Discoveries: Immune Homeostasis and the Microbiome—Dietary and Therapeutic Modulation and Implications for Transplantation. American Journal of Transplantation, 15(7), 1755–1758. DOI: https://doi.org/10.1111/ajt.13236
Forero, I. M., Ibarrola, A. S., & Díaz, P. V. (2007). Treatment of autoimmune diseases: A systems biology approach. Drug Discovery Today Therapeutic Strategies, 4(1), 57–62. DOI: https://doi.org/10.1016/j.ddstr.2007.08.005
Fox, I. J., Daley, G. Q., Goldman, S. A., Huard, J., Kamp, T. J., & Trucco, M. (2014). Use of differentiated pluripotent stem cells in replacement therapy for treating disease. Science, 345(6199). DOI: https://doi.org/10.1126/science.1247391
George, J., & Shoenfeld, Y. (2000). Introduction: The Immune System, the Autoimmune State and Autoimmune Disease. In Elsevier eBooks (pp. 1–15). DOI: https://doi.org/10.1016/b978-044450331-2/50002-3
Jaycox, J. R., Dai, Y., & Ring, A. M. (2024). Decoding the autoantibody reactome. Science, 383(6684), 705–707. DOI: https://doi.org/10.1126/science.abn1034
Kwiatkowski, A. J., Stewart, J. M., Cho, J. J., Avram, D., & Keselowsky, B. G. (2020). Nano and Microparticle Emerging Strategies for Treatment of Autoimmune Diseases: Multiple Sclerosis and Type 1 Diabetes. Advanced Healthcare Materials, 9(11). DOI: https://doi.org/10.1002/adhm.202000164
Lee, M. H., Shin, J. I., Yang, J. W., Lee, K. H., Cha, D. H., Hong, J. B., Park, Y., Choi, E., Tizaoui, K., Koyanagi, A., Jacob, L., Park, S., Kim, J. H., & Smith, L. (2022). Genome Editing Using CRISPR-Cas9 and Autoimmune Diseases: A Comprehensive Review. International Journal of Molecular Sciences, 23(3), 1337. DOI: https://doi.org/10.3390/ijms23031337
Li, A., Ojogho, O., & Escher, A. (2006). Saving Death: Apoptosis for Intervention in Transplantation and Autoimmunity. Journal of Immunology Research, 13(2–4), 273–282. DOI: https://doi.org/10.1080/17402520600834704
Li, B., Selmi, C., Tang, R., Gershwin, M. E., & Ma, X. (2018). The microbiome and autoimmunity: a paradigm from the gut–liver axis. Cellular and Molecular Immunology, 15(6), 595–609. DOI: https://doi.org/10.1038/cmi.2018.7
Li, T., Yang, Y., Qi, H., Cui, W., Zhang, L., Fu, X., He, X., Liu, M., Li, P., & Yu, T. (2023). CRISPR/Cas9 therapeutics: progress and prospects. Signal Transduction and Targeted Therapy, 8(1). DOI: https://doi.org/10.1038/s41392-023-01309-7
Mihaylova, N., & Tchorbanov, A. (2011). New Biotechnologycal Approaches for Immunotherapy of Autoimmune Diseases. Biotechnology & Biotechnological Equipment, 25(sup1), 24–29. DOI: https://doi.org/10.5504/bbeq.2011.0130
Moroncini, G., Calogera, G., Benfaremo, D., & Gabrielli, A. (2017). Biologics in Inflammatory Immune-mediated Systemic Diseases. Current Pharmaceutical Biotechnology, 18(12), 1008–1016. DOI: https://doi.org/10.2174/1389201019666171226152448
Mosanya, C. H., & Isaacs, J. D. (2018). Tolerising cellular therapies: what is their promise for autoimmune disease? Annals of the Rheumatic Diseases, 78(3), 297–310. DOI: https://doi.org/10.1136/annrheumdis-2018-214024
Mousa, W. K., Chehadeh, F., & Husband, S. (2022). Microbial dysbiosis in the gut drives systemic autoimmune diseases. Frontiers in Immunology, 13. DOI: https://doi.org/10.3389/fimmu.2022.906258
Munshi, N. V. (2016). CRISPR (Clustered Regularly Interspaced Palindromic Repeat)/Cas9 System. Circulation, 134(11), 777–779. DOI:

https://doi.org/10.1161/circulationaha.116.024007
Műzes, G., & Sipos, F. (2023). CAR-Based Therapy for Autoimmune Diseases: A Novel Powerful Option. Cells, 12(11), 1534. DOI: https://doi.org/10.3390/cells12111534
Newman, M., & Ausubel, F. M. (2016). Introduction to Gene Editing and Manipulation Using CRISPR/Cas9 Technology. Current Protocols in Molecular Biology, 115(1). DOI: https://doi.org/10.1002/cpmb.14
Ogata, A., & Tanaka, T. (2012). Tocilizumab for the Treatment of Rheumatoid Arthritis and Other Systemic Autoimmune Diseases: Current Perspectives and Future Directions. International Journal of Rheumatology, 2012, 1–14. DOI: https://doi.org/10.1155/2012/946048
Oh, S., & Payne, A. S. (2022). Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept. Immune Network, 22(5). DOI: https://doi.org/10.4110/in.2022.22.e37
Papanastasiou, A. D., Chatzantoni, K., & Mouzaki, A. (2008). Current therapeutic leads for the treatment of autoimmune diseases: stem cell transplantation and inhibition of post-translational modifications of autoantigens. Expert Opinion on Drug Discovery, 3(10), 1255–1265. DOI: https://doi.org/10.1517/17460441.3.10.1255
Pearson, R. M., Casey, L. M., Hughes, K. R., Miller, S. D., & Shea, L. D. (2017). In vivo reprogramming of immune cells: Technologies for induction of antigen-specific tolerance. Advanced Drug Delivery Reviews, 114, 240–255. DOI: https://doi.org/10.1016/j.addr.2017.04.005
Perico, L., Casiraghi, F., Sônego, F., Todeschini, M., Corna, D., Cerullo, D., Pezzotta, A., Isnard-Petit, P., Faravelli, S., Forneris, F., Thiam, K., Benigni, A., & Remuzzi, G. (2024). Bi-specific autoantigen-T cell engagers as targeted immunotherapy for autoreactive B cell depletion in autoimmune diseases. Frontiers in Immunology, 15. DOI: https://doi.org/10.3389/fimmu.2024.1335998
Pisetsky, D. S. (2023). Pathogenesis of autoimmune disease. Nature Reviews Nephrology, 19(8), 509–524. DOI: https://doi.org/10.1038/s41581-023-00720-1
Romano, M., Fanelli, G., Albany, C. J., Giganti, G., & Lombardi, G. (2019). Past, Present, and Future of Regulatory T Cell Therapy in Transplantation and Autoimmunity. Frontiers in Immunology, 10. DOI: https://doi.org/10.3389/fimmu.2019.00043
Rosenblum, M. D., Gratz, I. K., Paw, J. S., & Abbas, A. K. (2012). Treating Human Autoimmunity: Current Practice and Future Prospects. Science Translational Medicine, 4(125). DOI: https://doi.org/10.1126/scitranslmed.3003504
Sampath, B., Kathirvelu, P., & Sankaranarayanan, K. (2021). Stem Cell Therapy and Regenerative Medicine in Autoimmune Diseases. In IntechOpen eBooks. DOI: https://doi.org/10.5772/intechopen.89749
Smilek, D. E., & St Clair, E. W. (2015). Solving the puzzle of autoimmunity: critical questions. F1000Prime Reports, 7. DOI: https://doi.org/10.12703/p7-17
Smith, D. A., & Germolec, D. R. (1999). Introduction to immunology and autoimmunity. Environmental Health Perspectives, 107(suppl 5), 661–665. DOI: https://doi.org/10.1289/ehp.99107s5661
Steinman, L. (2004). Immune Therapy for Autoimmune Diseases. Science, 305(5681), 212–216. DOI: https://doi.org/10.1126/science.1099896
Sun, W., Zhang, Y., Guo, R., Sha, S., Chen, C., Ullah, H., Zhang, Y., Ma, J., You, W., Meng, J., Lv, Q., Cheng, L., Fan, S., Li, R., Mu, X., Li, S., & Yan, Q. (2024). A population-scale analysis of 36 gut microbiome studies reveals universal species signatures for common diseases. Npj Biofilms and Microbiomes, 10(1). DOI: https://doi.org/10.1038/s41522-024-00567-9
Talal, N. (1989). The goals of immunologic intervention in autoimmune disease. Journal of Autoimmunity, 2, 257–264. DOI: https://doi.org/10.1016/0896-8411(89)90138-8
Thatte, A. S., Billingsley, M. M., Weissman, D., Melamed, J. R., & Mitchell, M. J. (2024). Emerging strategies for nanomedicine in autoimmunity. Advanced Drug Delivery Reviews, 207, 115194. DOI: https://doi.org/10.1016/j.addr.2024.115194
Theofilopoulos, A. N., Kono, D. H., & Baccala, R. (2017). The multiple pathways to autoimmunity. Nature Immunology, 18(7), 716–724. DOI: https://doi.org/10.1038/ni.3731
Wang, L., Wang, F., & Gershwin, M. E. (2015). Human autoimmune diseases: a comprehensive update. Journal of Internal Medicine, 278(4), 369–395. DOI: https://doi.org/10.1111/joim.12395
Wang, M., Yuan, Q., & Xie, L. (2018). Mesenchymal Stem Cell-Based Immunomodulation: Properties and Clinical Application. Stem Cells International, 2018, 1–12. DOI: https://doi.org/10.1155/2018/3057624
Willyard, C. (2024). Can autoimmune diseases be cured? Scientists see hope at last. Nature, 625(7996), 646–648. DOI: https://doi.org/10.1038/d41586-024-00169-7
Xu, H., Liu, M., Cao, J., Li, X., Fan, D., Xia, Y., Lu, X., Li, J., Ju, D., & Zhao, H. (2019). The Dynamic Interplay between the Gut Microbiota and Autoimmune Diseases. Journal of Immunology Research, 2019, 1–14. DOI: https://doi.org/10.1155/2019/7546047
Yordanova, A. D., & Ivanova-Todorova, E. I. (2023). Therapeutic potential of mesenchymal stem cell-derived secretome in autoimmune patients. Rheumatology (Bulgaria), 31(1), 37–53. DOI: https://doi.org/10.35465/31.1.2023.pp37-53
Zhai, Y., Moosavi, R., & Chen, M. (2021). Immune Checkpoints, a Novel Class of Therapeutic Targets for Autoimmune Diseases. Frontiers in Immunology, 12, 645699. DOI: https://doi.org/10.3389/fimmu.2021.645699

Received: September 28, 2024 | Revised: October 21, 2024 | Accepted: October 29, 2024